Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II European trial of DPX-Survivac (EMD 640744) + temozolomide in patients with maximally resected newly-diagnosed glioblastoma

Next Previous
X
Search
Trial Profile

Phase II European trial of DPX-Survivac (EMD 640744) + temozolomide in patients with maximally resected newly-diagnosed glioblastoma

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maveropepimut-S (Primary) ; Dendritic cell vaccines; Temozolomide
  • Indications Glioblastoma
  • Focus Pharmacodynamics

    • Most Recent Events

    • 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
    • 20 Jan 2014 This trial is expected to start in the first half of 2014, according to a Immunovaccine media release.
    • 04 Jun 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top